// App-Quantinova.ai

P1014 : OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE

Researchers

Presenter

  • Andreas Reiter

Principal Investigators

  • Jason Gotlib

  • Ivn lvarez-Twose

  • Deepti H. Radia

  • Johannes Luebke

  • Priyanka J. Bobbili

  • Erin Sullivan

  • Melinda Louie-Gao

  • Juliana Schwaab

  • Ilene A. Galinsky

  • Cecelia Perkins

  • Wolfgang R. Sperr

  • Priya Sriskandarajah

  • Andi Chin

  • Mei Sheng Duh

  • Peter Valent

  • Daniel J. DeAngelo

Medical Centers

  • Institute of Mastocytosis Studies of Castilla La Mancha (CLMast) ─ Spanish Reference Center (CSUR) for Mastocytosis and CIBERONC,Virgen del Valle Hospital,Toledo,Spanien

  • Blueprint Medicines,Cambridge,United States

  • St Thomas' NHS Foundation Trust,London,Vereinigtes Königreich

  • Blueprint Medicines Corporation,Zug,Schwe

  • Medical Oncology,Dana-Farber Cancer Institute,Boston,Vereinigte Staaten

  • Department of Internal Medicine I, Division of Hematology and Hemostaseology and Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria

  • Department of Internal Medicine I, Division of Hematology and Hemostaseology and Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria

  • Blueprint Medicines Corporation,Zug,Швейцария

  • Blueprint Medicines Corporation,Cambridge,États-unis

  • Analysis Group, Inc., Boston, MA, United States

  • Department of Hematology and Oncology,University Hospital Mannheim, Heid

  • St Thomas' NHS Foundation Trust,Guy's Hosp

  • Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA

  • Blueprint Medicines Corporation,Zug,Schwe

  • Analysis Group, Inc., Boston, MA

  • Blueprint Medicines Corporation,Zug,Schwe

  • Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA

  • Blueprint Medicines Corporation,Zug,Schwe

  • Department of Hematology and Oncology, Universitätsklinikum Mannheim, Mannheim, Germany

  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

  • Blueprint Medicines Corporation,Zug,Schwe

  • Institute of Mastocytosis Studies of Castilla La Mancha (CLM

  • Analysis Group, Inc.,Boston,Verenigde Staten

  • Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital,London,Royaume-uni

  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

  • Blueprint Medicines Corporation,Zug,Schwe

  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

  • Blueprint Medicines,Cambridge,United States

  • Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital,London,United Kingdom

  • Blueprint Medicines Corporation,Cambridge,États-unis

  • Blueprint Medicines Corporation, Cambridge, MA

  • Analysis Group, Inc.,Boston,Verenigde Staten

  • Analysis Group Inc.,Boston, MA,Stati Uniti

  • Analysis Group, Inc.,Boston, MA,États-unis

  • Department of Radiation Oncology, Dana-Farber Cancer Institute Boston MA United States

  • Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA

  • Department of Hematology and Oncology,University Hospital Mannheim, Heid

  • Analysis Group Inc.,Boston, MA,Estados Unidos

  • Institute of Mastocytosis Studies of Castilla La Mancha (CLMast) ─ Spanish Reference Center (CSUR) for Mastocytosis and CIBERONC,Virgen del Valle Hospital,Toledo,Spanien

  • Blueprint Medicines Corporation,Zug,Schwe

  • Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA

  • Stanford Cancer Institute/Stanford University Sc

  • Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital,London,Royaume-uni

  • Department of Hematology and Oncology,University Hospital Mannheim, Heid

  • Blueprint Medicines,Cambridge,United States

  • Blueprint Medicines Corporation,Zug,Schwe

  • Haematology and Oncology, University Hospital of Mannheim, Mannheim, Germany

Locations

  • Germany

  • United States

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Autoimmune (AI)

Disease

  • Mastocytosis

  • Thrombocytopenia

  • Anemia

Biomarkers

  • ETV6-RUNX1

Drug/Treatment

  • Midostaurin

  • Cladribine

Outcome

  • N/A

Study Design

  • Observational

  • Multicenteric

Phase

  • II

Study Id's

  • NCT02561988

  • NCT03580655

  • NCT04695431

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved